British Alternative to Critical Migraine Drug Arrives in Israel After Yearlong Shortage
After nearly a year without access to the critical medication Slow-Darlin 80 mg, thousands of Israeli patients now have a British alternative available. The drug, containing propranolol hydrochloride in a sustained-release capsule form, is used to treat migraines, high blood pressure, and essential tremor. This new formulation provides a stable release of the active ingredient throughout the day, typically requiring less frequent dosing compared to immediate-release propranolol tablets.
The shortage, first revealed by Maariv, forced doctors to prescribe short-acting propranolol or other medications, requiring careful medical supervision due to potential changes in blood pressure, heart rate, migraine frequency, and side effects. Chronic migraine sufferers reported a resurgence of painful attacks during the shortage, which can last hours or days and severely impact daily functioning. Propranolol also helps reduce tremors that impair basic tasks like writing and holding objects.
Pharmacists explained that older, inexpensive drugs like propranolol often become unprofitable for importers, leading to supply gaps when production halts or distributors delay shipments. The Ministry of Health cautioned that the arrival of the new shipment does not guarantee immediate availability at all pharmacies, as distribution to health fund warehouses and branches may take several days. Patients are advised to check stock via apps, call centers, or pharmacies before visiting.
Medical professionals emphasize that patients should not switch to or start the new drug without consulting their doctor or pharmacist to ensure proper dosing and release form. The capsules must not be opened or crushed, as this alters the drug's release rate. Propranolol is contraindicated for individuals with asthma, certain heart conditions, or low blood pressure, and sudden discontinuation can worsen symptoms. Patients who changed treatments during the shortage should receive guidance before returning to the sustained-release formulation.
